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2330(1,2). As the myocardium has a
limited intrinsic capacity to restore
organ function after ischemic in-
jury (3–5), multimodal treatments
are used to alleviate symptoms and
improve clinical status in heart
failure. Current therapies target
impaired contractility and hemo-
dynamic decompensation without,however, treating the parenchymal loss that underlies the
development and progression of disease (6). To address this
unmet need, stem cell therapy is increasingly considered as
a potential means to fortify innate mechanisms of regenera-
tion (7–11). Stem cells traditionally isolated from bone
marrow, a readily used source, demonstrate excellent safety in
the clinical testing, yet patient-to-patient variability in repair
outcome remains a recognized limitation necessitating further
optimization (12–18).
By processing myocardial tissue excised during cardiac
surgery or obtained by endovascular biopsy, it is nowpossible to
derive resident stem cell populations (19,20). This advance
provides the prospect of anatomically matching the regenera-
tive cell source with the target organ. Such an approach is,
however, hampered by the invasive nature of heart tissue
sampling and the limited quantity of starting material. Ori-
enting bone marrow stem cells for cardiac repair would elim-
inate the need for the patient to undergo myocardial harvest,
rendering this accessible and renewable compartment an
alternative to heart tissue. Recently, hallmark traits of cardiac
development were successfully triggered within bonemarrow–
derived mesenchymal stem cells, establishing the ﬁrst human
scalable lineage-speciﬁed phenotype derived without heart
tissue harvest (21–24). Pre-clinical testing demonstrated that
cardiopoietic stem cells reliably repair the failing myocardium,
providing the foundation for clinical translation (22).
The ensuing C-CURE clinical trial addressed the feasi-
bility and safety of autologous bone marrow–derived car-
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3; accepted February 5, 2013.in patients with ischemic cardiomyopathy. This ﬁrst-in-class
biotherapeutics introduces a new strategy to optimize
regenerative intervention in heart failure.Methods
Study design and patient population. The multicenter
C-CURE clinical trial was approved by competent authorities
and ethics committees as a prospective, randomized, open, and
parallel 2-arm study in a stable heart failure population with
a history of myocardial infarction (Fig. 1). The primary study
endpoint was feasibility and safety at 2-year follow-up.
Secondary endpoints, assessed at 6 months, included cardiac
structure and function in tandemwithmeasures of global clinical
performance. The deﬁning inclusion criterionwas chronic heart
failure of ischemic origin with impaired left ventricular ejection
fraction (LVEF) (15% to 40%) (Online Table 1). Key inclusion
criteria were age (18 years of age and older and younger than
75 years of age), ischemic heart disease, and management
according to guidelines. Patients with an ischemic event at least
2 months before recruitment were eligible. At least 2 months
before enrollment, patients needed tobeoptimallymanaged and
revascularized. If patients were not already ﬁtted with an
implantable cardioverter-deﬁbrillator (ICD), one was provided.
Major exclusion criteria were previous cell therapy, myocardial
infarction or revascularization within 2 months before en-
rollment, ventricular aneurysm, and left ventricular wall
thickness <5 mm in the target territory documented by echo-
cardiography after patient consent and before randomization
(Online Table 1). Patients with moderate to severe aortic valve
disease or left ventricular thrombus were excluded, as were
patients who received a biventricular pacemaker within
6 months. Patients having a biventricular pacemaker for
>6 months and under stable pacing were permitted to join the
study. Patients (N ¼ 319) were screened at 9 clinical sites in
Europe (Belgium, Serbia, and Switzerland). The trial was
conducted from January 2009 to January 2012.
Randomization. In total, 48 patients were randomized
through a site-independent centralized process after exclu-
sion of 271 patients (of whom 249 did not meet inclusion/
exclusion criteria, 17 refused to participate, and 5 provided
consent after the recruitment cutoff date). Baseline data
demonstrated similar distribution of age, sex, body mass
index, prevalence of cardiovascular risk factors, and cardiac
disease history in study groups (Table 1). No difference in
medications or hemodynamics was observed. At the time of
consent, 1 patient refused participation, and on randomi-
zation, 2 patients were excluded because they did not meet
clinical inclusion criteria and no bone marrow was harvested,
2 were excluded because they did not meet bone marrow
inclusion criteria and declined repeat bone marrow harvest,
and 7 were excluded as quality control inclusion criteria were
not met and declined repeat bone marrow harvest (Fig. 1).
Patients in the control arm received standard of care com-
prising a beta-blocker, an angiotensin-converting enzyme
inhibitor or angiotensin receptor blocker, and a diuretic with
CHF of non-Ischemic origin
n=110
Patients Screened 
n=320
Age >75
n=79
Medically unstable (oncological 
illness, CRF on dialysis, other)
n=21
Comorbidities (BMI, aneurysm, LV 
thrombus, others)
n=12
NYHA class I or IV
n=11
Recent surgery or device 
implantation
n=7 LVEF >45%
n=6
Recent PCI
n=3 Refused or replied after recruitment 
period
n=22
Patients Randomized 
n=47
Control arm
n=15
Cell Therapy arm
n=32
Clinical inclusion criteria 
not met
n=2
Cell growth inclusion
criteria not met
n=2
C-Cure (Cell Therapy)
n=21
Consent Requested
n=48
Did not consent
n=1
Cell release inclusion
criteria not met
n=5
6-month follow-up
n=21
6-month follow-up
n=15
Patient died
n=2
Standard of Care (Control)
n=15
2-year safety follow-up
n=13
2-year safety follow-up
n=20
Bone marrow inclusion 
criteria not met
n=2
Elective heart transplant
n=1
Figure 1 Clinical Trial Design
The C-CURE trial is a prospective, randomized, 2-arm study. BMI ¼ body mass index; CHF ¼ chronic heart failure; CRF ¼ chronic renal failure; LV ¼ left ventricular; LVEF ¼ left
ventricular ejection fraction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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2331dosing and schedule tailored for maximal beneﬁt and
tolerability in accordance with practice guidelines for heart
failure management (25). Patients in the cell therapy arm
received, in addition to standard of care, bone marrow–
derived cardiopoietic stem cells meeting quality release
criteria. An independent centralized core laboratory masked
to study arm assignment and chronology of clinical evalua-
tion provided data analysis.
Cell production. Cell production consisted of mesenchymal
stem cell isolation and expansion, lineage speciﬁcation,
and cardiopoietic cell expansion. Speciﬁcally, human bone
marrow was harvested from the iliac crest with quality control
ensuring temperature control and sterility during trans-
portation between sites of collection and manufacturing.
Abiding by Good Manufacturing Practice, bone marrow was
cultured at 37C/5% CO2 in 175-cm
2
ﬂasks to purify
mesenchymal stem cells. Donor serology screening wasperformed for human immunodeﬁciency virus types 1 and 2,
syphilis, and hepatitis B and C. After 24 h, nonadherent bone
marrow and cellular debris were discarded, and adherent
mesenchymal stem cells were washed with phosphate-
buffered saline solution. A 1-to-1 passage (P0) was per-
formed to dissociate colony-forming units and allow for
expansion for up to 6 days in a culture medium (high-glucose
Dulbecco’s Modiﬁed Eagle’s Medium) supplemented with
5% human pooled platelet lysate media (Mayo Clinic Blood
Bank) (26) to generate a monolayer whereby 50  106 cells
were obtained. Lineage speciﬁcation was achieved by
mesenchymal stem cell exposure to a cardiogenic cocktail
regimen triggering expression and nuclear translocation of
cardiac transcription factors (Online Fig. 1) while main-
taining clonal proliferation (21,22,27). Passage P1 marked
the start of cardiogenic cocktail treatment in which cells were
cultured for 5 days in 5% platelet lysate–supplemented
Table 1
Patient Demographics, Cardiac History, and
Medication Proﬁle in Control and Cell Therapy Cohorts
Control Cell Therapy p Value
Age, yrs 59.5  8.0 55.7  10.4 0.82
Sex, M/F 22/2 20/1 0.63
Family history CAD 12 (50) 16 (73) 0.071
Smoking
Former 18 (75) 10 (48) 0.059
Current 5 (21) 6 (28) 0.81
Arterial hypertension 13 (54) 10 (45) 0.66
Diabetes mellitus 8 (33) 4 (18) 0.28
On diet 3 (13) 1 (5) 0.36
NIDDM 2 (8) 2 (9) 0.89
IDDM 3 (13) 1 (5) 0.36
Hypercholesterolemia 24 (100) 17 (77) 0.025
On diet 1 (4) 0 (0) 0.34
On statins 13 (96) 17 (77) 0.053
Cardiac history
ICD implant 8 (33) 11 (50) 0.20
CRT implant 2 (8) 1 (4.5) 0.63
PCI 21 (88) 18 (82) 0.86
CABG 8 (33) 5 (23) 0.48
Myocardial infarction 23 (96) 21 (100) 0.34
Q-wave 15 (86) 11 (73) 0.49
Other cardiac surgery 2 (8) 2 (9) 0.89
Sustained VT or VF 9 (38) 4 (18) 0.17
Atrial ﬁbrillation 3 (13) 4 (18) 0.55
Medication proﬁle
ACE inhibitor 19 (79) 18 (82) 0.57
ATR1-blocker 4 (20) 3 (14) 0.83
Beta-blocker 19 (79) 20 (91) 0.11
Diuretic agent 19 (79) 18 (82) 0.57
Antiplatelet agent 23 (96) 20 (91) 0.92
Statins 23 (96) 18 (82) 0.23
Hypoglycemic agent 4 (17) 3 (14) 0.83
Antiarrhythmic agent 4 (20) 9 (41) 0.053
Calcium antagonist 1 (4) 3 (14) 0.23
Nitrate or molsidomine 7 (29) 3 (14) 0.23
Values are mean  SD, n, or n (%).
ACE ¼ angiotensin-converting enzyme; ATR1-blocker ¼ angiotensin receptor-1 blocker; CABG ¼
coronary artery bypass graft; CAD ¼ coronary artery disease; CRT ¼ cardiac resuscitation therapy;
ICD ¼ implantable cardioverter-deﬁbrillator; IDDM ¼ insulin-independent diabetes mellitus; M/F ¼
male/female; NIDDM ¼ noninsulin-dependent diabetes mellitus; PCI ¼ percutaneous coronary
intervention; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.
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2332high-glucoseDulbecco’sModiﬁedEagle’sMedium containing
cardiogenic growth factors (i.e., 2.5 ng/ml transforming
growth factor-b, 5 ng/ml bone morphogenetic protein 4,
5 ng/ml activin A, 10 ng/ml ﬁbroblast growth factor 2,
100 ng/ml cardiotrophin, and 1 U/ml a-thrombin, synergized
by a diaminopyrimidine (100 nM 2-[(4-methoxyphenyl)
amino]-4-pyrimidinyl). Cell density was 4,000 cells/cm2
during mesenchymal stem cell culture and 1,500 cells/cm2
during cardiopoietic induction. Passages P2 and P3
marked the end of cardiogenic cocktail treatment followed
by expansion to yield 600  106 to 1,200  106 cells.
Harvest involved ﬁnal trypsinization, followed by concen-
tration in a preservation solution (HypoThermosol-FRS,
BioLifeSolutions, Bothell, Washington) for optimized
storage and transportation within a biocompatible container.Cells were centrally manufactured at a single accredited Good
Manufacturing Practice facility supporting trial sites. Cell
doses concentrated in the hypothermic preservation solution
were cool-packaged in biocompatible containers ﬁtted with
a thermometer capable of real-time temperature monitoring
to ensure environmental stability during transport. In parallel,
cell aliquots were maintained in the central core facility under
identical conditions with cellular viability conﬁrmed imme-
diately before administration. Cells packaged for trans-
portation were transplanted within 72 h of derivation.
Release criteria. The initial step in release ensured that the
stem cell yield obtained after cocktail exposure met the pre-
speciﬁed dose range required for inclusion in the cell therapy
arm, as documented for each patient (Online Fig. 2).
Consistency and quality control were carried out under
standard operating procedures to ensure purity, identity, and
homogeneity, along with sterility (Online Table 2) (28).
Purity assessment for each patient was documented by
comparing mesenchymal stem cells after cocktail exposure
with untreated counterparts using quantitative polymerase
chain reaction analysis of CD34, FABP4, osteocalcin, Sox9,
and Nestin corresponding to nonmesenchymal, adipose,
osteoblast, chondrocyte, and neuronal progenitors, respec-
tively, along with MYH7 indicating loss of multipotency
(Online Fig. 3). Impurity threshold was set to detect 1
alternate cell linage in 1,000,000 cells with a 2-fold gene
induction. Release criteria for cell identity included quanti-
tative polymerase chain reaction assessment with homoge-
neity validated by immunoﬂuorescence documentation of
MEF2c nuclear translocation in >140 cells for each patient
(Online Figs. 4 to 10). The immunoﬂuorescence threshold
of release was set at a minimum of 85% cells, demonstrating
a >2-fold induction of MEF2c in the nucleus versus cytosol,
documented for each patient (Online Fig. 11). Negative
controls included unguided mesenchymal stem cells demon-
strating low nucleus/cytosol MEF2c ratio (Online Fig. 12).
Sterility conﬁrmation documented products as free of viable
organisms, endotoxin, and mycoplasma. Production and
release, conforming to imposed standards, required 4 to 6
weeks of processing.
Clinical protocol. Cardiopoietic stem cells were adminis-
tered endoventricularly using the NOGA XP System with an
8-F Myostar catheter (Biologics Delivery Systems, Cordis
Corporation, Hialeah, Florida) (29,30). Electromechanical
mapping deﬁned areas of viable and dysfunctional myocar-
dium characterized by univoltage potential 4 mV and
reduced longitudinal linear shortening. Cells were injected
into mapped areas over 1 min per injection, with an average of
18 injections per patient (Fig. 2). Care was taken to spread
injections homogeneously, avoiding apical region and scar.
Patient follow-up was carried out per protocol. The ICD
threshold to detect ventricular tachycardia was set for rates
between 150 to 180 beats/min for fast ventricular tachycardia
between 180 and 220 beats/min, and for ventricular ﬁbrilla-
tion >220 beats/min. Two-dimensional transthoracic echo-
cardiography was performed in accordance with American
Figure 2 Intramyocardial Navigation and Mapping for Cell Delivery
Endomyocardial delivery of bone marrow–derived cardiopoietic stem cells using NOGA electromechanical guidance in the ﬁrst patient enrolled in the C-CURE trial. Upper color
coded panels show a right anterior oblique projection of unipolar voltage (left) and linear local shortening (LLS) maps (right). (Lower left and right) A bulls-eye view of electrical
and mechanical maps. Cells were delivered (brown dots) into areas of dysfunctional yet viable myocardium characterized by a voltage >4 mV (green color on the unipolar
map) with reduced LLS (red color on the LLS map).
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2333Society of Echocardiography guidelines. Left ventricular
dimensions were measured from parasternal long- or short-
axis views in tandem with apical 4-chamber, long-axis, and
2-chamber views. Electrocardiographic gating allowed left
ventricular volumetricmeasurements at end-diastole and end-
systole. LVEF was calculated using the biplane summation of
disks method (31). A 6-min walk test, a parameter of exercise
capacity, was performed according to American Thoracic
Society guidelines, recording the distance walked in a 6-min
period along a >30-m track (32). Spiroergometry was per-
formed per site practice.
Data analysis. Data were recorded using case report forms,
and accuracy was veriﬁed by medical monitors with source
documentation. Feasibility of intervention incorporated
assessment of cell expansion, manufacturing, and phenotype
release, in addition to catheter-based delivery. Safety was
assessed from ICD monitoring of cardiac arrhythmia, and
recording of adverse events was reviewed by an independent
data and safety monitoring board. Efﬁcacy signs included
left ventricular structure/function and clinical performance.
A composite clinical score (33) was created in an exploratory
fashion to discern the impact on heart failure, and integrated
New York Heart Association functional class, quality of life,
exercise and peak oxygen capacity, left ventricular dimen-
sion, and ejection fraction, along with hospitalization and
mortality. For each parameter, a score of þ1, 0, or 1 wasgiven for improvement, no change, or deterioration, re-
spectively. Thresholds were set as change of 10 ml in left
ventricular end-diastolic/end-systolic volume (ESV), 5 g/m2
in left ventricular mass index, 5% in ejection fraction, 20 m
in 6-min walking distance, 2 ml/kg/min VO2max, 10 points
in Minnesota Living With Heart Failure Questionnaire, 1
functional class in New York Heart Association classiﬁca-
tion, and presence/absence of hospitalization and mortality.
Baseline parameters and efﬁcacy parameters were compared
using the chi-square or Fisher exact test, as appropriate.
Composite clinical score was compared using independent
Student t tests; p < 0.05 was considered statistically signiﬁ-
cant. Data in text are presented with 95% conﬁdence intervals
and in ﬁgures as mean  SE unless otherwise indicated.Results
Feasibility. Bone marrow harvest and mesenchymal stem
cell isolation was achieved in 100% of cases (Fig. 3, steps 1 and
2A). Initial mesenchymal stem cell expansion was attained
with a 93% success rate (n¼ 28) (Fig. 3, step 2B).Guidance of
mesenchymal stem cells was successful in all lots passing initial
expansion (Fig. 3, step 3A). Manufacturing according to
predeﬁned release criteria for cell yield and purity produced
cardiopoietic stem cells at a dose >600  106 cells with 75%
success (n ¼ 21) (Fig. 3, step 3B). All lots passed karyotype
Figure 3
Cardiopoiesis, Inserted as a Lineage-Specifying Step,
Primes Patient-Derived Stem Cells for
Heart Failure Therapy
(A) In the C-CURE trial, after bone marrow harvest (step 1) and isolation/expan-
sion (steps 2A and 2B), patient-derived mesenchymal stem cells (hMSC) were
exposed to a cardiogenic growth factor cocktail (step 3A) followed by culture
expansion (step 3B). Derived cardiopoietic stem cells that conformed to quality
control release criteria were harvested and packaged for delivery (step 4) with
follow-up according to trial design (step 5). (B) Feasibility assessment
incorporated bone marrow harvest, hMSC scale-up, lineage speciﬁcation, and
endomyocardial delivery of cardiopoietic stem cells with follow-up.
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2334evaluation. Cardiopoietic stem cells were successfully deliv-
ered by endoventricular injections, under electromechanical
guidance, in all patients receiving cell therapy (Figs. 2 and 3B,
step 4).
Procedural safety. The elapsed period between time of
infarction and cell delivery was on average 1,540 days with
a minimum of 192 days and a maximum of 7,515 days. The
mean number of delivered cells was 733  106 (dose range,
605  1,168  106 cells extrapolated from pre-clinical
experience) administered in 9 to 26 injections in 4.5 to
12.7 ml. Femoral access was typically used. In 1 patient,
brachial access was required due to tortuosity of lower limb
arteries (34). In 1 patient, the procedure was accompanied by
ventricular tachycardia resolved by cardioversion. An additional
patient with pre-existing ophthalmic migraines experienced
blurred vision after intervention (Table 2). Overall, cell delivery
was well tolerated without relevant complications.
Adverse events. No subject was discontinued from the study
due to an adverse event. There was no evidence of systemic
toxicity induced by cardiopoietic stem cells. There was noevidence of uncontrolled tissue growth determined by serial
echocardiography. Cell administration was well tolerated with
no difference in cardiac or noncardiac events between study
groups (Table 2). In the control group, 2 patients died at 18 and
20 months post-randomization due to heart failure deterio-
ration and sudden cardiac death, respectively (Table 2). In the
cell therapy group, in 1 patient who underwent elective cardiac
transplantation at 21 months post-randomization, post-
operative sepsis developed, and the patient died (Table 2).
Throughout the 24-month follow-up period, no event was
reportedwith a deﬁnite or probable relationship to cell therapy.
A possible relationship to cell administration was reported in
a patientwith ventricular tachycardia documented before study
enrollment who had recurrence presenting with slow mono-
morphic episodes at 98 and 182 days after cell delivery that
resolved on cardioversion. Per protocol, ICDprogrammingwas
applied in 14 control and 12 cell-treated patients. In controls,
ICD programming was personalized in 4 patients from study
initiation, and in the other 6, programming was changed on
follow-up at the discretion of the treating cardiologist or due to
arrhythmia. In the cell therapygroup, 1patient hadpersonalized
ICD programming at study start, whereas in 8, programming
was changed by the treating cardiologists. Serial ICD readings
revealed a comparable incidence of newly occurring ventricular
tachycardia and ventricular ﬁbrillation in either group over the
2-year observation period (Table 2).
Efﬁcacy signs. Cardiac function, assessed in each individual
by echocardiography at 6 months (Fig. 4A), demonstrated a
7% increase in the LVEF with cell therapy from 27.5% (95%
conﬁdence interval [CI]: 25.5% to 29.5%) to 34.5% (95% CI:
32.5% to 36.6%) (n¼ 21, p< 0.0001) (Fig. 4B). The LVEF
was unchanged from 27.8% (95% CI: 25.8% to 29.8%) to
28.0% (95% CI: 26.1% to 30.6%) in the control group (n ¼
15) (Figs. 4A and 4B). Cell therapy signiﬁcantly reduced the
ESV by 24.8  3.0 ml (95% CI: 30.7 ml to 18.9 ml)
comparedwith8.8 3.9ml (95%CI:16.4ml to1.2ml)
in the control group (p < 0.001) (Fig. 4C). Reduction in left
ventricular end-diastolic volume was18ml (95%CI:25.5
ml to10.5ml) versus9ml (95%CI:15.0ml to3.6ml)
in the cell therapy group versus the control group, respectively
(Fig. 4C). The percentage of change in the LVEF, at
6 months, as a function of the ESV (Fig. 4D) or end-diastolic
volume (Fig. 4E) percentage of change indicated that car-
diopoietic cell therapy extended the therapeutic beneﬁt of
standard of care for cardiac function and structure (35). The
6-min walk test, an index of cardiovascular performance,
signiﬁcantly improved from 394m (95%CI: 346m to 442m)
to 456 m (95% CI: 391 m to 521 m) in cell-treated patients,
whereas it decreased from 419 m (95% CI: 382 m to 456 m)
to 404 m (95%CI: 350 m to 458 m) in the control group (p<
0.01), with a difference of 77 m favoring cell therapy at
6 months (Fig. 5A). The Minnesota Living With Heart
FailureQuestionnaire (36), ameasure of health-related quality
of life, improved with cell therapy albeit without reaching
signiﬁcance compared with the control group (Fig. 5B). To
assess the percentage of patients who demonstrated
Table 2 Safety Evaluation
Cardiac Adverse Events
Timing Group Prior Control Prior Cell Rx Post Control Post Cell Rx New Event Control New Event Cell Rx
Death 0 (0%) 0 (0%) 2 (8%) 0 (0%) 2 (8%) 0 (0%)
Elective transplant 0 (0%) 0 (0%) 0 (0%) 1 (5%)* 0 (0%) 1 (5%)*
Cardiac disorder 2 (8%) 5 (24%) 15 (62%) 16 (76%) 13 (54%) 11 (52%)
SV arrhythmia 1 (4%) 3 (14%) 7 (29%) 9 (43%) 6 (25%) 6 (28%)
Ventricular ﬁbrillation 0 (0%) 0 (0%) 1 (4%) 1 (5%) 1 (4%) 1 (5%)
Ventricular tachycardia 1 (4%) 2 (10%) 8 (33%) 6 (20%) 7 (29%) 4 (19%)
Medical Adverse Events
Control Cell Therapy Relation to Cell Therapy p Value
Gastrointestinal disorders 1 (4.2%) 2 (9.6%) Not related 0.47
Upper abdominal pain 1 (4.2%) 1 (4.8%)
Inguinal hernia 1 (4.8%)
Retroperitoneal hematoma
General disorders 5 (21%) Not applicable 0.026
Chest pain 2 (8.4%)
Fatigue 1 (4.2%)
General deterioration 1 (4.2%)
Pyrexia 1 (4.2%)
Hepatobiliary disorder 0 1 (4.8%) Not related 0.28
Cholecystitis 1 (4.8%)
Nervous system disorder 1 (4.2%) 1 (4.8%) Possible 0.92
Blurred vision 1 (4.2%) 1 (4.8%)
Subdural hematoma
Musculoskeletal disorder 1 (4.2%) 0.34
Intervertebral disk hernia 1 (4.2%)
Respiratory, thoracic and mediastinal disorder 3 (12.6%) 5 (24%) Not related 0.32
Bronchial irritation 1 (4.2%) 1 (4.8%) Not related
Pulmonary Edema 1 (4.2%) 1 (4.8%) Not related
COPD 1 (4.2%) 1 (4.8%) Not related
Cough 1 (4.8%) Not related
Dyspnea 1 (4.8%)
Hemoptysis
Surgical and medical procedures 1 (4.2%) 1 (4.8%) Not related 0.92
Cholecystectomy 1 (4.2%) 1 (4.8%) Not related
Knee arthroplasty
Peripheral vascular disorder 1 (4.2%) Not applicable 0.34
Claudication 1 (4.2%)
Analysis revealed no statistical signiﬁcance between groups (p > 0.05). *Death resulted as a complication following elective heart transplantation.
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2335improvement or deterioration for each monitored endpoint,
the impact of standard of care versus standard of care plus
cardiopoietic stem cells was quantiﬁed on left ventricular
structure and function, quality of life, exercise capacity, peak
oxygen uptake, New York Heart Association functional class,
along with heart failure–related hospitalization and cardiac
mortality (Fig. 5C, Online Table 3). The improvement ach-
ieved with standard of care alone was most affected with the
addition of cell therapy for the LVEF, ESV, and the 6-min
walk (Fig. 5C, Online Table 3). Post-hoc analysis, including
a composite clinical score integrating outcome measures (33),
corroborated the beneﬁt of cell therapy (Online Fig. 13).
Discussion
The C-CURE clinical trial assessed cardiopoietic stem cell
intervention as an adjunct to chronic heart failuremanagement. This is the ﬁrst application of guided stem
cells for targeted regeneration of a failing organ. Lineage
priming of bone marrow stem cells from patients with
ischemic heart failure was shown to be feasible. Adminis-
tration of derived autologous cardiopoietic stem cells into
the hibernating myocardium of patients with heart failure
was safe. The study demonstrated consistent improvement
of the LVEF with cardiopoietic stem cell therapy compared
with standard of care. By introducing lineage guidance into
the cell therapy protocol, the C-CURE trial provides initial
clinical evidence of a new approach to cardiovascular
regenerative medicine.
To date, clinical studies have used bone marrow stem
cells in their native lineage–unspeciﬁed state, as unfractio-
nated or puriﬁed cell products largely in the setting of acute
or subacute myocardial infarction (9–18,35,37–40). The
Figure 4
Impact of Cardiopoietic Stem Cell Therapy on
Cardiac Function and Structure at 6-Month Follow-Up
(A) Changes in left ventricular ejection fraction (D LVEF) for each patient. Control
group includes patients who received standard of care alone. The cell therapy
group includes patients who received standard of care plus cardiopoietic stem
cells. (B) Median values for LVEF before and 6 months after treatment. (C)
Changes in left ventricular end-diastolic volume (EDV) and end-systolic volume
(ESV) (D, E) Impact of cardiopoietic stem cell therapy (Cell Therapy) on left
ventricular remodeling compared with standard-of-care alone (Control). Changes
in LVEF are plotted against changes in left ventricular ESV (D) and EDV (E).
Change reﬂects the difference between parameters measured before and
6 months after therapy.
C 
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Figure 5 Global Beneﬁt of Cardiopoietic Stem Cell Therapy
(A) Change (D) in 6-min walk distance. (B) Change (D) in the Minnesota (MN)
Living With Heart Failure (HF) Questionnaire score. (C) Percentage of patients
showing improvement or deterioration in left ventricular end-diastolic volume
(EDV), left ventricular end-systolic volume (ESV), left ventricular ejection mass
index (Mass Index), peak oxygen uptake (VO2 Max); 6-min walk test (Walk);
Minnesota Living with Heart Failure Questionnaire (MNQOL); New York Heart
Association (NYHA) functional class, along with heart failure–related hospitaliza-
tion (Hospitalization) and cardiac mortality (Survival) with standard of care (Control)
versus those receiving standard of care plus cardiopoietic stem cells (Cell
Therapy). Change reﬂects difference between parameters measured before and
6 months after therapy.
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2336molecular substrate of advanced heart failure requires distinct
regenerative strategies adequate to restore parenchymal
integrity and prevent progressive remodeling (41,42). Human
bone marrow stem cells are a desirable source for organ repair
due to accessibility for harvest, propensity to propagate in
culture, favorable biological proﬁle, and extensive clinical
experience (43–45). However, when derived from heart
failure patients, bone marrow mesenchymal stem cells dem-
onstrate latent plasticity with variable spontaneous capacity to
instigate regeneration (22,46,47). Recent studies have used
excised heart tissue, obtained at the time of cardiac bypass or
by endomyocardial biopsy, to anatomically match the stem
cell source to the target organ of repair (19,20). The rationale
for the present clinical study is based on pre-clinical evidence
that pre-emptive guidance optimizes repair potency despite
a noncardiac source of stem cell derivation (22).
Induction of the cardiopoietic stem cell state is intended
to ensure the regenerative beneﬁt of mesenchymal stem cellsderived from patients with heart failure. Cardiopoiesis is
promoted through replication of natural cues decoded from
endoderm-mediated cardiogenic guidance of the mesoderm
(21,22,48–50). A set of recombinant factors here converted
mesenchymal stem cells from patients with ischemic heart
failure to yield a Good Manufacturing Practice grade, scal-
able biologics meeting pre-set quality control release criteria.
Repeat manufacturing runs were imposed when the stem cell
proliferative capacity was insufﬁcient to derive the target
dose. The inability to grow a critical mass of cells in and of
itself has been suggested to be an outcome prognosticator
(51). However, post-hoc analysis of data from patients not
meeting cell quality inclusion criteria did not support this
premise. Rather, in this study, bone marrow harvest, spec-
imen anticoagulation, and/or cryopreservation were noted on
retrospective quality review to compromise starting material
and ultimate cell yield in line with previous studies (52). In
this way, the quality standards pre-imposed in this study
ensured that cells released for delivery into patients were
adherent to a phenotype associated with repair beneﬁt (22).
From time of delivery and through follow-up, car-
diopoietic stem cell transplantation demonstrated a safety
proﬁle equivalent to standard of care. Endomyocardial
delivery was associated acutely with a transient increase in
cardiac enzymes, remaining within values previously reported
with myocardial injections (29). Corroborating pre-clinical
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2337ﬁndings (22), no long-term evidence of uncontrolled tissue
growth or proarrhythmogenic risk was associated with expo-
sure to cardiopoietic stem cells. Prospective, 2-year surveil-
lance conﬁrmed clinical safety.
Although not powered as a therapeutic efﬁcacy trial, a
beneﬁt for left ventricular function was documented here with
cardiopoietic stem cell treatment. Although in principle,
varying cell doses and injection numbers could confound
interpretation, pre-clinical data showed no dose dependence
on outcome within the range used here. Improved LVEF, as
observed at 6 months in the present study, is a powerful
predictor of beneﬁcial cardiovascular outcome in heart failure
(53,54), and was here associated with a reduced ESV,
consistent with reversal of pathological remodeling (35).
Study limitations. The present study was limited in
assessing the change in myocardial regeneration or perfusion
because modalities, such as magnetic resonance imaging and
single-photon emission computed tomography, were
precluded due to incompatibility with patient population or
unavailability at all participating sites. A composite score
comprising, in addition to changes in cardiac structure and
function, quality of life and clinical endpoints improved with
cardiopoietic stem cell therapy beyond standard of care alone.
These data collectively highlight the potential of lineage-
speciﬁed stem cells to meet the regenerative requirements
of ischemic heart failure, particularly in select patients in
whom revascularization, resynchronization, and pharmaco-
therapy failed to restore pump function. In this initial clinical
experience, procurement and delivery of cardiopoietic stem
cells, as well as safety and efﬁcacy proﬁles, showed equiva-
lence across distinct socioeconomic and health care settings,
an early indicator that this new therapy can potentially
reach broader populations in need. Ultimately, the rigor
of comparative effectiveness outcome analysis (55) will be
needed to inform on the value of introducing a personalized
regenerative strategy in heart failure management.
Conclusions
Organ failure is a major global challenge with the aging of
the population and the shortage of donor organs (56–58).
The past decade realized translation of stem cell–based
technology to formulate an emergent clinical trial experience
(59–61). The present C-CURE trial introduces a potential
new treatment for heart failure using readily accessible bone
marrow mesenchymal stem cells lineage speciﬁed to upgrade
cardioregenerative aptitude. This trial is the ﬁrst to capture
the beneﬁt of lineage speciﬁcation without the need for
harvesting heart tissue as a stem cell source. This novel class
of stem cells was optimized in proof-of-concept pre-clinical
studies establishing superior beneﬁt compared with unspec-
iﬁed stem cells (22). Clinical translation of cardiopoietic stem
cell therapy, performed here in patients with ischemic heart
failure, demonstrates that insertion of a lineage guidance
step does not alter the feasibility and safety established with
naïve bone marrow stem cell therapy, yet confers a favorableimpact on myocardial remodeling, LVEF, and global well-
ness beyond what has been reported in heart failure with
unguided bone marrow stem cells or as compared head-to-
head in this trial with standard of care alone. The C-CURE
trial thus advances the paradigm of lineage speciﬁcation in
stem cell therapy, providing a rationale for further clinical
validation.
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